The research group in hematology is devoted to clinical and translational trials in hematology, focused on diagnosis, prognosis and the development of new therapies to treat hematological malignancies such as leukemias and myelomas.
The group uses a variety of approaches such as genetic studies of the immune response, pharmacogenomics in response to treatment, analysis of polymorphisms as disease predictors and the study of cell populations using flow cytometry for the characterization of residual disease.
Through our research, we aim to:
Investigate biological, clinical, and epidemiological aspects of hematological diseases
Carry out translational research projects focused on finding prognostic factors or treatment response predictors
Carry out clinical research, promoting participation in clinical trials for hematological diseases and participating in national and international cooperative groups.